Inspira Technologies Oxy B.H.N. (NASDAQ:IINN) Coverage Initiated by Analysts at Litchfield Hills Research

Litchfield Hills Research began coverage on shares of Inspira Technologies Oxy B.H.N. (NASDAQ:IINN) in a research note released on Monday morning,Benzinga reports. The brokerage issued a buy rating and a $2.00 price objective on the stock.

Inspira Technologies Oxy B.H.N. Stock Performance

IINN opened at $0.62 on Monday. Inspira Technologies Oxy B.H.N. has a 12-month low of $0.40 and a 12-month high of $2.31. The business’s fifty day simple moving average is $0.58 and its 200-day simple moving average is $0.86. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.23 and a quick ratio of 2.13.

Institutional Investors Weigh In On Inspira Technologies Oxy B.H.N.

A number of institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC boosted its position in Inspira Technologies Oxy B.H.N. by 422.5% during the fourth quarter. Citadel Advisors LLC now owns 86,763 shares of the company’s stock valued at $88,000 after purchasing an additional 70,159 shares in the last quarter. Virtu Financial LLC boosted its holdings in Inspira Technologies Oxy B.H.N. by 254.4% in the first quarter. Virtu Financial LLC now owns 47,015 shares of the company’s stock worth $31,000 after acquiring an additional 33,749 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Inspira Technologies Oxy B.H.N. by 142.7% in the fourth quarter. Renaissance Technologies LLC now owns 36,622 shares of the company’s stock worth $37,000 after acquiring an additional 21,532 shares in the last quarter. Institutional investors own 12.72% of the company’s stock.

About Inspira Technologies Oxy B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.